APOBEC3B gene overexpression in non‑small-cell lung cancer

Sasaki,Hidefumi; Suzuki,Ayumi; Tatematsu,Tsutomu; Shitara,Masayuki; Hikosaka,Yu; Okuda,Katsuhiro; Moriyama,Satoru; Yano,Motoki; Fujii,Yoshitaka

doi:10.3892/br.2014.256

APOBEC3B gene overexpression in non‑small-cell lung cancer

Authors:
- Hidefumi Sasaki
- Ayumi Suzuki
- Tsutomu Tatematsu
- Masayuki Shitara
- Yu Hikosaka
- Katsuhiro Okuda
- Satoru Moriyama
- Motoki Yano
- Yoshitaka Fujii
View Affiliations

Affiliations: Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi 467‑8601, Japan
Published online on: March 18, 2014 https://doi.org/10.3892/br.2014.256
Pages: 392-395

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent study results have demonstrated that a subclass of apolipoprotein B mRNA‑editing enzyme, catalytic polypeptide‑like (APOBEC) cytidine deaminase may induce mutation clusters in various types of cancer. From the Cancer Genome Altas, an APOBEC mutation pattern was identified in bladder, cervical, breast, head and neck and lung cancers. In the present study, APOBEC3B mRNA expression was investigated using quantitative reverse transcription‑polymerase chain reaction (RT‑qPCR) assay using LightCycler in surgically treated non‑small-cell lung cancer (NSCLC) cases. Additionally, 88 surgically removed Japanese NSCLC cases were analyzed for mRNA level. The results showed that APOBEC3B/β‑actin mRNA levels were significantly higher in lung cancer (1,598.481±6,465.781) when compared to adjacent normal lung tissues (2,116.639±8,337.331, P=0.5453). The tumor/normal (T/N) ratio of APOBEC3B/β‑actin mRNA levels was not different within the gender, age, smoking status and pathological stages. The T/N ratio of APOBEC3B/β‑actin mRNA levels was not significantly different in epidermal growth factor receptor (EGFR) or Kras mutation‑positive cases as compared to the wild‑type cases.

View Figures

View References

1	Ginsberg RJ, Kris K and Armstrong G: Cancer of the lung. Principles and Practice of Oncology. 4th edition. Lippincott; Philadelphia, PA: pp. 673–682. 1993
2	Committee for Scientific Affairs. Sakata R, Fujii Y and Kuwano H: Thoracic and cardiovascular surgery in Japan during 2009: annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 59:636–667. 2011. View Article : Google Scholar : PubMed/NCBI
3	Postmus PE: Chemotherapy for non-small cell lung cancer: the experience of the Lung Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. Chest. 113(Suppl 1): S28–S31. 1998. View Article : Google Scholar : PubMed/NCBI
4	Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
5	Loeb LA: Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 51:3075–3079. 1991.PubMed/NCBI
6	Conticello SG: Creative deaminases, self-inflicted damage, and genome evolution. Ann NY Acad Sci. 1267:79–85. 2012. View Article : Google Scholar : PubMed/NCBI
7	Smith HC, Bennett RP, Kizilyer A, McDougall WM and Prohaska KM: Functions and regulation of the APOBEC family of proteins. Semin Cell Dev Biol. 23:258–268. 2012. View Article : Google Scholar : PubMed/NCBI
8	Nik-Zainal S, Alexandrov LB, Wedge DC, et al: Mutational processes molding the genomes of 21 breast cancers. Cell. 149:979–993. 2012. View Article : Google Scholar : PubMed/NCBI
9	Roberts SA, Sterling J, Thompson C, et al: Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. Mol Cell. 46:424–435. 2012. View Article : Google Scholar : PubMed/NCBI
10	Burns MB, Lackey L, Carpenter MA, et al: APOBEC3B is an enzymatic source of mutation in breast cancer. Nature. 494:366–370. 2013.PubMed/NCBI
11	Roberts SA, Lawrence MS, Klimczak LJ, et al: An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet. 45:970–976. 2013. View Article : Google Scholar : PubMed/NCBI
12	Harris RS, Petersen-Mahrt SK and Neuberger MS: RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol Cell. 10:1247–1253. 2002. View Article : Google Scholar : PubMed/NCBI
13	Beale RC, Petersen-Mahrt SK, Watt IN, et al: Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J Mol Biol. 337:585–596. 2004. View Article : Google Scholar : PubMed/NCBI
14	Vartanian JP, Guetard D, Henry M and Wain-Hobson S: Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science. 320:230–233. 2008. View Article : Google Scholar : PubMed/NCBI
15	Loeb LA: Human cancers express mutator phenotypes: origin, consequences and targeting. Nat Rev Cancer. 11:450–457. 2011. View Article : Google Scholar : PubMed/NCBI
16	Conticello SG, Langlois MA, Yang Z and Neuberger MS: DNA deamination in immunity: AID in the context of its APOBEC relatives. Adv Immunol. 94:37–73. 2007. View Article : Google Scholar : PubMed/NCBI
17	Taylor BJ, Nik-Zainal S, Wu YL, et al: DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. Elife. 2:e005342013. View Article : Google Scholar : PubMed/NCBI
18	Chan K, Sterling JF, Roberts SA, Bhagwat AS, Resnick MA and Gordenin DA: Base damage within single-strand DNA underlies in vivo hypermutability induced by a ubiquitous environmental agent. PLoS Genet. 8:e10031492012. View Article : Google Scholar : PubMed/NCBI
19	Lada AG, Dhar A, Boissy RJ, et al: AID/APOBEC cytosine deaminase induces genome-wide kataegis. Biol Direct. 7:472012. View Article : Google Scholar : PubMed/NCBI
20	Stenglein MD, Burns MB, Li M, Lengyel J and Harris RS: APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat Struct Mol Biol. 17:222–229. 2010. View Article : Google Scholar : PubMed/NCBI
21	Landry S, Narvaiza I, Linfesty DC and Weitzman MD: APOBEC3A can activate the DNA damage response and cause cell-cycle arrest. EMBO Rep. 12:444–450. 2011. View Article : Google Scholar : PubMed/NCBI